01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
A recent decision of the North Carolina Court of Appeals serves as an important reminder to avoid th...
Read More >
This week, over a five-part podcast series, we have considered some of the basic questions around mo...
Read More >
Below is the Federal Policy team’s weekly preview, posted when Congress is in session. HEADLINES -...
Read More >
The EEOC recently released guidance to assist those employers filling out their EEO-1 reports who ha...
Read More >
While litigation against special purpose acquisition companies (“SPACs”) has been historically rar...
Read More >
While it feels like we just finished the EEO-1 reporting season, the time is here again to start pre...
Read More >